News

How do you know when a former favorite dividend stock is no longer one you should buy, or hold? Some would say it's time to look away as soon as the profits the company uses to make dividend

Income-seeking investors tend to be drawn to high dividend yields. The higher the yield, the better a dividend becomes at generating income that can fund an investor's spending as well as beat

Income-seeking investors tend to be drawn to high dividend yields. The higher the yield, the better a dividend becomes at generating income that can fund an investor's spending as well as beat

A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech (NASDAQ: BNTX) stock on Monday. As of late-session trading that day, the once-hot biotech's share price had

A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech (NASDAQ: BNTX) stock on Monday. As of late-session trading that day, the once-hot biotech's share price had

Shares of Mesoblast (NASDAQ: MESO) were down by more than 15% as of 11:45 a.m. ET on Monday, just days after the healthcare stock plunged more than 61% on bad news regarding one of its lead therapy

Image source: The Motley Fool.

Axsome Therapeutics (NASDAQ: AXSM)Q2 2023 Earnings CallAug 07, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Sage Therapeutics (NASDAQ: SAGE) were crashing 51.2% lower as of 11:27 a.m. ET on Monday. The huge sell-off came after the company and its partner, Biogen, announced following the market

Shares of Sage Therapeutics (NASDAQ: SAGE) were crashing 51.2% lower as of 11:27 a.m. ET on Monday. The huge sell-off came after the company and its partner, Biogen, announced following the market

Shares of Sage Therapeutics (NASDAQ: SAGE) were crashing 51.2% lower as of 11:27 a.m. ET on Monday. The huge sell-off came after the company and its partner, Biogen, announced following the market

Last year was no small challenge for many investors, but the tides appear to have shifted for the better so far in 2023. Some companies have even performed well throughout all these ups and downs.

Last year was no small challenge for many investors, but the tides appear to have shifted for the better so far in 2023. Some companies have even performed well throughout all these ups and downs.

Last year was no small challenge for many investors, but the tides appear to have shifted for the better so far in 2023. Some companies have even performed well throughout all these ups and downs.

Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime

Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime

Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime

Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results

Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results

Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results

What's a great thing to do during the hot month of August? One option is to find somewhere cool. Another is to invest in stocks that could deliver their own kind of sizzle.

We asked three Motley

Shares of Mesoblast (NASDAQ: MESO) were down more than 61% as of 2:15 p.m. on Friday. The pharmaceutical stock is down more than 54% so far this year.

Mesoblast focuses on allogeneic cellular

Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be

Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be